Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $196.56 billion. The enterprise value is $222.77 billion.
| Market Cap | 196.56B |
| Enterprise Value | 222.77B |
Important Dates
The next confirmed earnings date is Thursday, April 24, 2025, before market open.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | Mar 17, 2025 |
Share Statistics
Merck & Co. has 2.52 billion shares outstanding. The number of shares has decreased by -0.24% in one year.
| Current Share Class | 2.52B |
| Shares Outstanding | 2.52B |
| Shares Change (YoY) | -0.24% |
| Shares Change (QoQ) | -0.16% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 80.15% |
| Float | 2.51B |
Valuation Ratios
The trailing PE ratio is 11.59 and the forward PE ratio is 8.72. Merck & Co.'s PEG ratio is 1.14.
| PE Ratio | 11.59 |
| Forward PE | 8.72 |
| PS Ratio | 3.12 |
| Forward PS | 3.03 |
| PB Ratio | 4.32 |
| P/TBV Ratio | 23.95 |
| P/FCF Ratio | 10.95 |
| P/OCF Ratio | 9.23 |
| PEG Ratio | 1.14 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.65, with an EV/FCF ratio of 12.31.
| EV / Earnings | 13.01 |
| EV / Sales | 3.47 |
| EV / EBITDA | 7.65 |
| EV / EBIT | 8.95 |
| EV / FCF | 12.31 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.83.
| Current Ratio | 1.36 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | 1.30 |
| Debt / FCF | 2.11 |
| Interest Coverage | 19.58 |
Financial Efficiency
Return on equity (ROE) is 40.79% and return on invested capital (ROIC) is 19.62%.
| Return on Equity (ROE) | 40.79% |
| Return on Assets (ROA) | 13.90% |
| Return on Invested Capital (ROIC) | 19.62% |
| Return on Capital Employed (ROCE) | 28.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.36 |
Taxes
In the past 12 months, Merck & Co. has paid $2.80 billion in taxes.
| Income Tax | 2.80B |
| Effective Tax Rate | 14.06% |
Stock Price Statistics
The stock price has decreased by -37.80% in the last 52 weeks. The beta is 0.42, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -37.80% |
| 50-Day Moving Average | 88.54 |
| 200-Day Moving Average | 104.13 |
| Relative Strength Index (RSI) | 30.80 |
| Average Volume (20 Days) | 18,726,866 |
Short Selling Information
The latest short interest is 37.94 million, so 1.51% of the outstanding shares have been sold short.
| Short Interest | 37.94M |
| Short Previous Month | 40.94M |
| Short % of Shares Out | 1.51% |
| Short % of Float | 1.51% |
| Short Ratio (days to cover) | 2.19 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $64.17 billion and earned $17.12 billion in profits. Earnings per share was $6.74.
| Revenue | 64.17B |
| Gross Profit | 49.47B |
| Operating Income | 24.89B |
| Pretax Income | n/a |
| Net Income | 17.12B |
| EBITDA | 29.13B |
| EBIT | 24.89B |
| Earnings Per Share (EPS) | $6.74 |
Balance Sheet
The company has $13.69 billion in cash and $38.27 billion in debt, giving a net cash position of -$24.58 billion or -$9.77 per share.
| Cash & Cash Equivalents | 13.69B |
| Total Debt | 38.27B |
| Net Cash | -24.58B |
| Net Cash Per Share | -$9.77 |
| Equity (Book Value) | 46.37B |
| Book Value Per Share | 18.32 |
| Working Capital | 10.36B |
Cash Flow
In the last 12 months, operating cash flow was $21.47 billion and capital expenditures -$3.37 billion, giving a free cash flow of $18.10 billion.
| Operating Cash Flow | 21.47B |
| Capital Expenditures | -3.37B |
| Free Cash Flow | 18.10B |
| FCF Per Share | $7.19 |
Margins
Gross margin is 77.09%, with operating and profit margins of 38.79% and 26.68%.
| Gross Margin | 77.09% |
| Operating Margin | 38.79% |
| Pretax Margin | 31.07% |
| Profit Margin | 26.68% |
| EBITDA Margin | 45.40% |
| EBIT Margin | 38.79% |
| FCF Margin | 28.20% |
Dividends & Yields
This stock pays an annual dividend of $3.24, which amounts to a dividend yield of 4.15%.
| Dividend Per Share | $3.24 |
| Dividend Yield | 4.15% |
| Dividend Growth (YoY) | 5.33% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 48.07% |
| Buyback Yield | 0.24% |
| Shareholder Yield | 4.35% |
| Earnings Yield | 8.64% |
| FCF Yield | 9.13% |
Analyst Forecast
The average price target for Merck & Co. is $119.86, which is 53.45% higher than the current price. The consensus rating is "Buy".
| Price Target | $119.86 |
| Price Target Difference | 53.45% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 2.58% |
| EPS Growth Forecast (5Y) | 8.86% |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 4.65 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.65 |
| Piotroski F-Score | 7 |